• GenSpera Inc., of San Antonio, presented interim data from its ongoing Phase I trial of G-202 in patients with advanced solid tumor cancers. The main conclusions are that G-202 appeared to be well tolerated when administered via the recommended dosing regimen and that it should be evaluated in Phase II studies.